Drug Profile
JB 991
Alternative Names: JB991Latest Information Update: 11 Feb 2020
Price :
$50
*
At a glance
- Originator Synphora
- Developer Swedish Orphan Biovitrum; Synphora
- Class Anti-inflammatories; Prostaglandins; Skin disorder therapies
- Mechanism of Action Apoptosis stimulants; Prostaglandin agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Atopic dermatitis
Highest Development Phases
- No development reported Glaucoma; Psoriasis
Most Recent Events
- 11 Feb 2020 JB 991 is available for licensing as of 11 Feb 2020.
- 23 Feb 2010 No development reported - Phase-II for Psoriasis in Sweden (Topical)
- 23 Feb 2010 No development reported - Preclinical for Glaucoma in Sweden (Topical)